<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02644083</url>
  </required_header>
  <id_info>
    <org_study_id>IRB 11364</org_study_id>
    <nct_id>NCT02644083</nct_id>
  </id_info>
  <brief_title>Tecfidera and MRI for Brain Energy in MS</brief_title>
  <official_title>Modulation of Cerebral Grey Matter High Energy Phosphate Metabolites in Multiple Sclerosis by Dimethyl Fumarate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Biogen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Oregon Health and Science University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to test the hypothesis that DMF can improve
      mitochondrial function in the brain of people with MS. The investigators will assess
      mitochondrial function in the cerebral grey matter by measuring PCr and ATP by 31P magnetic
      resonance spectroscopy (MRS) and NAA in NAWM by 1H MRS.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2016</start_date>
  <completion_date type="Anticipated">February 2018</completion_date>
  <primary_completion_date type="Anticipated">February 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in phosphocreatine (PCr) in cerebral grey matter</measure>
    <time_frame>baseline and 6 months of treatment with Dimethyl Fumarate (DMF)</time_frame>
    <description>PCr levels evaluated by magnetic resonance spectroscopy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in ATP in normal appearing white matter (NAWM)</measure>
    <time_frame>baseline and 6 months of treatment with Dimethyl Fumarate</time_frame>
    <description>ATP levels evaluated by magnetic resonance spectroscopy</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Changes in fatigue</measure>
    <time_frame>baseline and 6 months of treatment with DMF</time_frame>
    <description>as assessed by Fatigue Severity Scale (FSS), Modified Fatigue Impact Scale (MFIS),</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in fatigue</measure>
    <time_frame>baseline and 6 months of treatment with DMF</time_frame>
    <description>as assessed by Modified Fatigue Impact Scale (MFIS),</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in cognition</measure>
    <time_frame>baseline and 6 months of treatment with DMF</time_frame>
    <description>as assessed by the symbol digit modalities test (SDMT)</description>
  </other_outcome>
  <enrollment type="Anticipated">21</enrollment>
  <condition>Multiple Sclerosis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dimethyl fumarate</intervention_name>
    <other_name>Tecfidera</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        21 patients with a diagnosis of relapsing-remitting multiple sclerosis
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of MS by 2010 McDonald criteria

          -  Relapsing clinical course

          -  Ages 18-55

          -  Laboratory values that allow initiation of dimethyl fumarate (Tecfidera)

        Exclusion Criteria:

          -  Systemic disease associated with cerebrovascular disease (e.g. diabetes mellitus,
             hypertension, hyperlipidemia, coronary heart disease)

          -  Treatment with corticosteroids or disease-modifying therapies (interferon beta,
             glatiramer acetate, natalizumab, fingolimod, teriflunomide) within 30 days of the
             first baseline MRI scan.

          -  Treatment at any time with mitoxantrone, cyclophosphamide, or any other long acting
             immunosuppressant

          -  Prior treatment of greater than 1 month at any time with DMF

          -  Inability to tolerate MRI procedures

          -  Pregnant/breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rebecca Spain, MD, MSPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oregon Health and Science University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anna Orban</last_name>
    <phone>503-494-3549</phone>
    <email>orban@ohsu.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Orban</last_name>
      <phone>503-494-3549</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 23, 2015</study_first_submitted>
  <study_first_submitted_qc>December 29, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 31, 2015</study_first_posted>
  <last_update_submitted>September 26, 2016</last_update_submitted>
  <last_update_submitted_qc>September 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oregon Health and Science University</investigator_affiliation>
    <investigator_full_name>Rebecca Spain</investigator_full_name>
    <investigator_title>Dr Rebecca Spain, MD, MSPH</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dimethyl Fumarate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

